 MT-001 is a novel protein component vaccine candidate that has been shown to confer long-lasting immunity against multiple SARS-CoV-2 strains, including Delta and Omicron BA.1 variants. It is designed for easy manufacturing and distribution, making it a potentially valuable addition to the existing toolbox of SARS-CoV-2 vaccines. This article was authored by Elliot Campbell, Julie Dobkin, Louis J. Osorio, and others.